Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology · Bioinfo & AI

[Dynamically monitoring circulating tumor DNA as a biomarker for immunotherapy in advanced esophageal squamous cell carcinoma]

Summary

This study investigated the clinical value of dynamic monitoring of circulating tumor DNA (ctDNA) in 94 patients with advanced esophageal squamous cell carcinoma (ESCC) receiving sintilimab. The findings indicate that the ctDNA-based molecular tumor burden index (mTBI) serves as a sensitive, real-time biomarker for evaluating immunotherapy efficacy. Patients achieving ctDNA clearance or having a low mTBI after two treatment cycles demonstrated significantly delayed tumor progression and improved overall survival. Dynamic mTBI monitoring showed high consistency with concurrent imaging assessments, suggesting its utility for personalized treatment management.

Critical appraisal

Clinical. This phase II/III study (derived from the ORIENT-2 trial) demonstrates that dynamic monitoring of ctDNA and the molecular tumor burden index (mTBI) is a predictive biomarker for sintilimab immunotherapy response in advanced ESCC patients. CtDNA clearance after 2 cycles is associated with significantly delayed tumor progression (HR=2.05), and low mTBI is linked to better DCR (73.5% vs 38.2%), PFS (HR=2.80), and OS (HR=3.54). These findings suggest that mTBI could guide real-time treatment decisions, potentially allowing for intensification or modification of treatment in early non-responders, with a potential clinical impact in the medium term (3-5 years) for optimizing immunotherapy strategies.

Molecular biology. Targeted sequencing of plasma ctDNA was used to detect somatic variants and assess molecular tumor burden. Frequently mutated genes included TP53 (82%), CDKN2B (23%), and NOTCH1 (22%). CCND1 copy number variation was associated with shorter PFS (HR=1.88). The use of liquid biopsy (plasma) offers a non-invasive approach for dynamic monitoring, overcoming the limitations of repeated tissue biopsies. The measurement of mTBI and detection of ctDNA clearance provide sensitive, real-time molecular information, validating ctDNA as a translational biomarker for monitoring treatment response.

Bioinfo & AI. The study involved the calculation of the molecular tumor burden index (mTBI) from targeted ctDNA sequencing data. This calculation represents a bioinformatic application to quantify tumor burden and track its dynamics. The high consistency between dynamic mTBI changes and radiological assessments (RECIST 1.1) validates this approach. While no novel algorithm is presented, the integration and analysis of ctDNA data to generate a predictive score like mTBI is a clinical bioinformatics application that could eventually be deployed to prioritize patients requiring re-evaluation or treatment modification within a clinical workflow.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology